The Global Favipiravir Market Size valued for USD 170 Million in 2021 and is anticipated to reach USD 246 Million by 2030 with a CAGR of 4.3% from 2022 to 2030.

Favipiravir is an antiviral medication that is primarily used to treat influenza A and B viruses. It is a pyrazinecarboxamide derivative that inhibits influenza virus replication by interfering with the viral RNA polymerase. Favipiravir has received Emergency Use Authorization (EUA) in some countries as a potential COVID-19 treatment, though its efficacy and safety profile for COVID-19 treatment are still being investigated. The medication has been shown to be both safe and effective in the treatment of patients with mild to moderate COVID-19.

Favipiravir is typically administered as tablets, which are taken twice daily, with or without food. The standard treatment duration for influenza is 14 days, and for COVID-19 it is 14 to 28 days. Nausea, diarrhoea, and anaemia are common favipiravir side effects. It should be noted that favipiravir is still an experimental treatment for COVID-19 and should only be used under the supervision of a healthcare professional. Before beginning treatment, patients should be informed of the drug's potential benefits and risks.

Favipiravir is also being researched for the treatment of other viral infections such as dengue fever and Marburg virus disease. Before being used for other indications, the safety and efficacy of this drug, like any other, should be established across clinical trials and regulatory approval.

Favipiravir Market Dynamics

The global favipiravir market is expected to expand significantly as the global incidence of influenza infections rises and there is a greater demand for effective antiviral drugs. Because favipiravir has been approved for emergency use in some countries, the COVID-19 pandemic has increased demand for it as a potential treatment option for the virus.

The rising global incidence of influenza infections is increasing the demand for effective antiviral drugs like favipiravir. Because it has been approved for emergency use in some countries, the COVID-19 pandemic has expanded the market for favipiravir as a potential treatment option for the virus. Favipiravir has been shown in clinical trials to be effective in treating influenza, which is driving its adoption as a treatment option.

The availability of alternative influenza treatments, such as neuraminidase inhibitors, and the absence of clinical data supporting the efficacy of favipiravir in treating COVID-19, may limit market growth. Furthermore, favipiravir is still in the experimental stage for COVID-19 treatment, and its efficacy and safety profile must be established through additional research.

Favipiravir Market Insights

The Favipiravir market is split into disease, end-user, and regional segments. The disease category is divided into influenza viruses and coronavirus (COVID-19), severe acute respiratory syndrome (SARS), ebola, and others. Based on End-User, the market is split into hospital, clinics, drug store, and others. Furthermore, the region segment is categorized into North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

Global Favipiravir Market Geographical Competition

The main markets for favipiravir are North America and Europe because there are many pharmaceutical businesses and research facilities in these areas. These areas also have a strong healthcare infrastructure and high healthcare spending, which is propelling the market's expansion.

Due to the region's expanding need for efficient antiviral medications and the region's rising influenza prevalence, the Asia Pacific market is anticipated to rise rapidly. The need for favipiravir as a viable therapeutic option in this area has increased as a result of the COVID-19 pandemic.

Global Favipiravir Industry Segment Analysis

Market By Disease

·         Influenza Viruses

·         Coronavirus (COVID-19) Severe

·         Acute Respiratory Syndrome (SARS)

·         Ebola

·         Others

Market By End-User

·         Hospital

·         Clinics

·         Drug Store

·         Others

Favipiravir Market Leading Companies

The players profiled in the report are Beacon Pharmaceuticals, Beximco Pharmaceuticals Limited, ChemRar Group, Cipla Limited, Fujifilm Toyama Chemical Co., Ltd, Glenmark Pharmaceuticals, Hisun Pharm, Lasa Supergenerics Limited, Medivector, Inc, Sihuan Pharmaceuticals, and Zhejiang Hisun Pharmaceutical Co., Ltd.

Favipiravir Market Regions